Literature DB >> 19770847

Endoscopic and pathological aspects of colitis-associated dysplasia.

Fiona D M van Schaik1, G Johan A Offerhaus, Marguerite E I Schipper, Peter D Siersema, Frank P Vleggaar, Bas Oldenburg.   

Abstract

The risk of developing colorectal cancer in patients with colitis-associated dysplasia is considerable. Surveillance programs in patients with ulcerative colitis and Crohn's disease aim to detect dysplastic lesions early and rely heavily on taking random biopsy samples along the length of the colon. Diagnosing dysplasia can be difficult because of the heterogeneous endoscopic appearance of dysplasia and the poor interobserver agreement among pathologists when grading dysplasia. Colitis-associated dysplasia may present as a dysplasia-associated lesion or mass (DALM), which may be indistinguishable from a sporadic adenoma in non-colitic tissue, or may arise in flat mucosa of endoscopically normal appearance. Information about the endoscopic appearance, the colonic distribution and the histopathological grade of colitis-associated dysplasia is required to define the optimal treatment. This Review summarizes the endoscopic and histopathological features of colitis-associated dysplasia and the requirements for optimal interaction between endoscopists and pathologists, with the aim of reducing the uncertainties in the diagnosis of dysplastic lesions and improving the management of colitis-associated dysplasia.

Entities:  

Mesh:

Year:  2009        PMID: 19770847     DOI: 10.1038/nrgastro.2009.162

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  71 in total

1.  Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis-related dysplasia.

Authors:  N A Wong; N J Mayer; S MacKell; H M Gilmour; D J Harrison
Journal:  Histopathology       Date:  2000-08       Impact factor: 5.087

2.  Management of low and high-grade dysplasia in inflammatory bowel disease: the gastroenterologists' perspective and current practice in the United Kingdom.

Authors:  Titus Thomas; Prakash Nair; Mike W Dronfield; John F Mayberry
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-12       Impact factor: 2.566

3.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis.

Authors:  Ralf Kiesslich; Martin Goetz; Katharina Lammersdorf; Constantin Schneider; Juergen Burg; Manfred Stolte; Michael Vieth; Bernhard Nafe; Peter R Galle; Markus F Neurath
Journal:  Gastroenterology       Date:  2007-01-31       Impact factor: 22.682

5.  Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential.

Authors:  U Broomé; R Löfberg; B Veress; L S Eriksson
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

6.  Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis?

Authors:  Wojciech Blonski; Rabi Kundu; James Lewis; Faten Aberra; Mark Osterman; Gary R Lichtenstein
Journal:  Scand J Gastroenterol       Date:  2008       Impact factor: 2.423

7.  Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy.

Authors:  M O Blackstone; R H Riddell; B H Rogers; B Levin
Journal:  Gastroenterology       Date:  1981-02       Impact factor: 22.682

8.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

9.  Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis.

Authors:  W R Connell; J E Lennard-Jones; C B Williams; I C Talbot; A B Price; K H Wilkinson
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

10.  Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial.

Authors:  James F Marion; Jerome D Waye; Daniel H Present; Yuriy Israel; Carol Bodian; Noam Harpaz; Mark Chapman; Steven Itzkowitz; Adam F Steinlauf; Maria T Abreu; Thomas A Ullman; James Aisenberg; Lloyd Mayer
Journal:  Am J Gastroenterol       Date:  2008-09       Impact factor: 10.864

View more
  5 in total

1.  [WHO classification 2010 for the lower gastrointestinal tract: what is new?].

Authors:  D E Aust
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

Review 2.  Clonal evolution of colorectal cancer in IBD.

Authors:  Chang-Ho R Choi; Ibrahim Al Bakir; Ailsa L Hart; Trevor A Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-02-08       Impact factor: 46.802

3.  15-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL-6/STAT3 signaling pathway.

Authors:  Fei Mao; Min Xu; Xiangsheng Zuo; Jiang Yu; Weiguo Xu; Micheline J Moussalli; Elias Elias; Haiyan S Li; Stephanie S Watowich; Imad Shureiqi
Journal:  FASEB J       Date:  2015-02-24       Impact factor: 5.191

4.  Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview.

Authors:  Chang-Ho Ryan Choi; Matthew D Rutter; Alan Askari; Gui Han Lee; Janindra Warusavitarne; Morgan Moorghen; Siwan Thomas-Gibson; Brian P Saunders; Trevor A Graham; Ailsa L Hart
Journal:  Am J Gastroenterol       Date:  2015-03-31       Impact factor: 10.864

5.  Sonic hedgehog inhibitors prevent colitis-associated cancer via orchestrated mechanisms of IL-6/gp130 inhibition, 15-PGDH induction, Bcl-2 abrogation, and tumorsphere inhibition.

Authors:  Napapan Kangwan; Yoon-Jae Kim; Young Min Han; Migyeong Jeong; Jong-Min Park; Eun-Jin Go; Ki-Baik Hahm
Journal:  Oncotarget       Date:  2016-02-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.